Transthyretin Amyloid Cardiomyopathy Clinical Trial
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
This pilot study will determine the efficacy of ION-682284 in reducing the amyloid deposit on the heart tissue compared to placebo.
To participate in the ION-682884-CS2MRI sub-study, participants must meet all inclusion criteria of the study protocol ION-682884-CS2 (NCT04136171).
Contraindication or sensitivity to MRI contrast agents
Orthopnea of sufficient severity to preclude supine scanning at screening.
Weight or body girth exceeds the limits of the cardiac MRI machine specifications.
Contraindication to cardiac MRI scanning, as assessed by local MRI safety questionnaire/checklist.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 11 Locations for this study
Boston Massachusetts, 02115, United States
Portland Oregon, 97239, United States
Florence , 50139, Italy
Padova , 35128, Italy
Majadahonda , 28222, Spain
Bellshill , ML4 3, United Kingdom
Birmingham , B15 2, United Kingdom
Cardiff , CF15 , United Kingdom
London , NW3 2, United Kingdom
London , SE1 1, United Kingdom
Manchester , M15 6, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.